A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma-Reference-Cited by-同舟云学术

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma

Author:

Kushner Brian H.¹,Cheung Nai-Kong V.¹,Modak Shakeel¹,Becher Oren J.²,Basu Ellen M.¹,Roberts Stephen S.¹,Kramer Kim¹,Dunkel Ira J.¹

Affiliation:

1. Department of Pediatrics; Memorial Sloan Kettering Cancer Center; New York NY

2. Department of Pediatrics; Duke University Medical Center; Durham NC

Funder

NIH/NCI Cancer Center Support Grant

Gerber Foundation, Fremont, MI; the Robert Steel Foundation, New York, NY; Katie's Find A Cure Fund, New York, NY

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

2. The PI3K pathway as drug target in human cancer;Courtney;J Clin Oncol Off J Am Soc Clin Oncol,2010

5. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine;Sun;OncoTargets Ther,2012

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Oncology in Pediatric Cancer Surgery;Surgical Oncology Clinics of North America;2023-12